Article · Wikipedia archive · Last revised Aug 5, 2026

Evogliptin

Evogliptin is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs. It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea and Russia. In a meta-analysis involving data from 6 randomized controlled trials, Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin.

Last revised
Aug 5, 2026
Read time
≈ 1 min
Length
211 w
Citations
4
Source
Wikipedia ↗
Evogliptin
Clinical data
Trade namesSuganon
Other namesDA-1229
Routes of
administration		By mouth
ATC code
Identifiers
  • (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-{[(2-methyl-2-propanyl)oxy]methyl}-2-piperazinone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H26F3N3O3
Molar mass401.430 g·mol−1
3D model (JSmol)
  • CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N
  • InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
  • Key:LCDDAGSJHKEABN-MLGOLLRUSA-N

Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.1 It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea2 and Russia.3 In a meta-analysis involving data from 6 randomized controlled trials (887 patients), Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. 4

References

References

  1. McCormack PL (November 2015). "Evogliptin: First Global Approval". Drugs. 75 (17): 2045–9. doi:10.1007/s40265-015-0496-5. PMID 26541763. S2CID 46450821.
  2. "Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea". pipelinereview.com. October 2, 2015. Archived from the original on June 30, 2022. Retrieved February 1, 2017.
  3. "Evodine (evogliptin) film-coated tablets. Full prescribing information". Russian State Register of Medicines (in Russian).
  4. Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (Nov 2020). "Efficacy and Safety of Novel Dipeptidyl-Peptidase-4 Inhibitor Evogliptin in the Management of Type 2 Diabetes Mellitus: A Meta-Analysis". Indian J Endocrinol Metab. 24 (5): 434–445. doi:10.4103/ijem.IJEM_418_20. PMC 7810058. PMID 33489850.